ArticleBritish journal of cancer2001
Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review.British journal of cancer · 2010Pooled it
- Interactions Between Circulating Tumor Cells and the Immune System in Colorectal Cancer: Friends or Foes?Cancers · 2026Review
- Mechano-inhibition of endocytosis sensitizes cancer cells to Fas-induced Apoptosis.Cell death & disease · 2024Article
- Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer.International journal of molecular sciences · 2022Review
- Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes.Frontiers in oncology · 2022Article
- Pro-tumorigenic role of type 2 diabetes-induced cellular senescence in colorectal cancer.Frontiers in oncology · 2022Review
- Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding.Renal failure · 2018Article
- Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.Oncogene · 2018Review
- Early septic insult in neonatal pigs increases serum and urinary soluble Fas ligand and decreases kidney function without inducing significant renal apoptosis.Renal failure · 2017Article
- Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes.Scientific reports · 2016Article
- MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3.Molecular cancer · 2015Article
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients.Molecular medicine (Cambridge, Mass.) · 2014Article
- Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2013Article
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.Cancer · 2013Article
- MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.Oncogene · 2012Article
- Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis.Critical care (London, England) · 2011Article
- Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.World journal of gastrointestinal oncology · 2010Article
- The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.Journal of cancer research and clinical oncology · 2010Article
- FasL gene knock-down therapy enhances the antiglioma immune response.Neuro-oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of membrane-bound Fas ligand (mFasL) on colon cancer cells serves as a potential mechanism to inhibit host immune function by inducing apoptosis of host lymphocytes. Membrane-bound FasL can be cleaved and released as a soluble mediator (sFasL), which may spread the apoptosis induction effect. Our study examined whether colon adenocarcinoma cells release sFasL, and induce apoptosis of host lymphocytes without direct cell-cell contact. In 12 consecutive patients with colon adenocarcinoma mFasL was identified in the tumours, sFasL was measured in the sera and apoptosis identified in tumour-infiltrating and peripheral blood lymphocytes. To analyse the function of sFasL, colon cancer cells were primarily cultured; sFasL was isolated from supernatants, measured, incubated with Fas-bearing Jurkat cells, and the resulting apoptosis was analysed. Serum levels of sFasL were significantly elevated in all colon cancer patients with mFasL expression in tumour tissues (n = 8). In these patients, the number of apoptotic lymphocytes was significantly increased within tumour and peripheral blood. Furthermore, sFasL was present in the corresponding supernatants and induced apoptosis of Jurkat cells in a dose-dependent manner. These findings suggest that mFasL-positive colon cancer cells release sFasL, and thus may induce apoptosis of host lymphocytes as a potential mechanism for immune evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.